The P-I study evaluates Rybrevant as a monotx. and in combination with Lazertinib in 780 patients that showed long-term response and safety, m-OS was 23mos. after a median follow-up of 19.2mos., 2yr. OS rate of 47%, ORR (37%), m-DOR of 12.5mos. and m-PFS of 6.9mos.
Treatment with Rybrevant resulted in consistent efficacy across post-platinum patients with EGFR exon 20 insertion mutations, 42% had sustained clinical response, and m-DoR was 7.5mos. with ongoing treatment in 13%, 7 are progression-free & 8 received treatment beyond the progression
No new safety signals were seen, and the incidence of treatment-related AEs leading to dose interruption, reduction & discontinuation was 29%/18%/7%, respectively. The results were presented at ELCC 2023
Ref: PR Newswire | Image: Janssen
Related News:- Janssen Reports P-II Trial Results of Nipocalimab for the Treatment of Severe Hemolytic Disease
